Structure-pharmacokinetics relationship of series of aminosteroidal neuromuscular blocking agents in the cat

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 3, 2000, Pages 861-869

  Proost, Johannes H ^a,b,c   Wierda, J Mark K H ^b   Houwertjes, Martin C ^b   Roggeveld, Jan ^a,b   Meijer, Dirk K F ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3ALPHA ACETOXY 17ALPHA BUTYRYLOXY 2BETA PIPERIDINO 5ALPHA ANDROSTAN 16BETA YL) 1 METHYLPIPERIDINIUM BROMIDE; 1 (3ALPHA ACETOXY 17BETA BUTYRYLOXY 2BETA PIPERIDINO 5ALPHA ANDROSTAN 16BETA YL) 1 ALLYLPIPERIDINIUM BROMIDE; 1 (3ALPHA ACETOXY 17BETA BUTYRYLOXY 2BETA PIPERIDINO 5ALPHA ANDROSTAN 16BETA YL) HEXAHYDRO 1 METHYL 1H AZEPINIUM BROMIDE; 2BETA,16BETA DIPIPERIDINO 5ALPHA ANDROSTAN 3ALPHA OL ACETATE DIMETHOBROMIDE; 3 DEACETYLVECURONIUM; NEUROMUSCULAR BLOCKING AGENT; ORG 20059; ORG 20297; ORG 9273; ORG 9453; ORG 9498; ORG 9955; PANCURONIUM; PIPECURONIUM; RAPACURONIUM BROMIDE; ROCURONIUM; UNCLASSIFIED DRUG; VECURONIUM;

ANIMAL EXPERIMENT; ARTICLE; BOLUS INJECTION; CAT; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; LIPOPHILICITY; NEUROMUSCULAR BLOCKING; NONHUMAN; PARTITION COEFFICIENT; PHARMACOKINETICS; PRIORITY JOURNAL;

ANIMALS; BILE; CATS; LIVER; MALE; NEUROMUSCULAR BLOCKING AGENTS; PROTEIN BINDING; SOLUBILITY; STEROIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034008667     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Agoston S, Crul EJ, Kersten UW, Houwertjes MC and Scaf AHJ (1977) The relationship between disposition and duration of action of a congeneric series of steroidal neuromuscular blocking agents. Acta Anaesthesiol Scand 21:24-30.
2. Agoston S, Kersten UW and Meijer DKF (1973) The fate of pancuronium bromide in the cat. Acta Anaesthesiol Scand 17:129-135.
3. Agoston S, Vandenbrom RHG, Wierda JMKH, Houwertjes MC and Kersten UW (1988) Pharmacokinetics and disposition of pipecuronium bromide in the cat. Eur J Anaesthesiol 5:233-242.
4. Bencini AF, Scaf AHJ, Agoston S, Houwertjes MC and Kersten UW (1985) Disposition of vecuronium bromide in the cat. Br J Anaesth 57:782-788.
5. Bencini AF, Scaf AHJ, Sohn YJ, Kersten-Kleef UW and Agoston S (1986) Hepatobiliary disposition of vecuronium bromide in man. Br J Anaesth 58:988-995.
6. Boxenbaum HG, Riegelman S and Elashoff RM (1974) Statistical estimation in pharmacokinetics. J Pharmacokinet Biopharm 2:123-148.
7. Cutler DJ (1987) Definition of mean residence times in pharmacokinetics. Biopharm Drug Dispos 8:87-97.
8. Donati F (1988) Onset of action of relaxants. Can J Anaesth 35:S52-S58.
9. Draper NR and Smith H (1981) Applied Regression Analysis. John Wiley & Sons, New York.
10. Hughes MA, Glass PSA and Jacobs JR (1992) Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 76:334-341.
11. Khuenl-Brady KS, Castagnoli KP, Canfell PC, Caldwell JE, Agoston S and Miller RD (1990) The neuromuscular blocking effects and pharmacokinetics of Org 9426 and Org 9616 in the cat. Anesthesiology 72:669-674.
12. Kleef UW, Proost JH, Roggeveld J and Wierda JMKH (1993) Determination of rocuronium and its putative metabolites in body fluids and tissue homogenates. J Chromatogr 621:65-76.
13. Koepsell H (1998) Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol 60:243-266.
14. Meijer DKF, Smit JW and Müller M (1997) Hepatobiliary elimination of cationic drugs: The role of P-glycoproteins and other ATP-dependent transporters. Adv Drug Deliv Rev 25:159-200.
15. Mol WEM and Meijer DKF (1990) Hepatic transport mechanisms for bivalent organic cations. Subcellular distribution and hepato-biliary concentration gradients of some steroidal muscle relaxants. Biochem Pharmacol 39:383-390.
16. Neef C and Meijer DKF (1984) Structure-pharmacokinetics relationship of quaternary ammonium compounds. Correlation of physicochemical and pharmacokinetic parameters. Naunyn Schmiedeherg's Arch Pharmacol 328:111-118.
17. Noy N and Zakim D (1993) Physical chemical basis for the uptake of organic compounds by cells, in Hepatic Transport and Bile Secretion: Physiology and Pathophysiology (Tavoloni N and Berk PD eds) pp 313-335, Raven Press, New York.
18. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, Sanathanan L, Schentag JJ, Shah VP, Sheiner LB, Skelly JP, Stanski DR, Temple RJ, Viswanathan CT, Weissinger J and Yacobi A (1992) Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 51:465-473.
19. Press WH, Flannery BP, Teukolsky SA and Vetterling WT (1986) Numerical Recipes. Cambridge University Press, Cambridge.
20. Proost JH, Roggeveld J, Wierda JMKH and Meijer DKF (1997) Relationship between chemical structure and physicochemical properties of series of bulky organic cations and their hepatic uptake and biliary excretion rates. J Pharmacol Exp Ther 282:715-726.
21. Proost JH, Wierda JMKH and Meijer DKF (1996) An extended pharmacokinetic/ pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs. J Pharmacokinet Biopharm 24:45-77
22. Rekker RF (1977) Hydrophobic aspects of binding, in Biological Activity and Chemical Structure (Keverling Buisman JA ed) pp 107-130. Elsevier Publishing Co., Amsterdam.
23. Russo EA, Lees GE and Hightower D (1986) Evaluation of renal function in cats, using quantitative urinalysis. Am J Vet Res 47:1308-1312.
24. Sandker GW, Weert B, Olinga P, Wolters H, Slooff MJH, Meijer DKF and Groothuis GMM (1994) Characterization of transport in isolated human hepatocytes. A study with the bile acid taurocholic acid, the uncharged ouabain and the organic cations vecuronium and rocuronium. Biochem Pharmacol 47:2193-2200.
25. Segredo V, Shin YS, Sharma ML, Gruenke LD, Caldwell JE, Khuenl-Brady KS, Agoston S and Miller RD (1991) Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (Org 7268) in cats. Anesthesiology 74: 1052-1059.
26. Seydel JK and Schaper K-J (1982) Quantitative structure-pharmacokinetic relationships and drug design. Pharmacol Ther 15:131-182.
27. Shafer SL and Stanski DR (1992) Improving the clinical utility of anesthetic drug pharmacokinetics. Anesthesiology 76:327-330.
28. Smit JW, Duin E, Steen H, Oosting R, Roggeveld J and Meijer DKF (1998) Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level. Br J Pharmacol 123:361-370.
29. Van der Sluijs P and Meijer DKF (1985) Binding of drugs with a quaternary ammonium group to alpha-1 acid glycoprotein and asialo alpha-1 acid glycoprotein. J Pharmacol Exp Ther 234:703-707.
30. Veng Pedersen P (1977) Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokinet Biopharm 5:513-531.
31. Wagner JG (1975) Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications, Hamilton, IL.
32. Waser PG (1973) Localization of 14C-pancuronium by histo- and wholebody autoradiography in normal and pregnant mice. Naunyn Schmiedeberg's Arch Pharmacol 279:399-412.
33. Wierda JMKH, Proost JH, Muir AW and Marshall RJ (1993) Design of drugs for rapid onset. Anaesth Pharmacol Rev 1:57-68.
34. Zhang L, Brett CM and Giacomini KM (1998) Role of organic cation transporters in drug absorption and elimination. Annu Rev Pharmacol Toxicol 38:431-460.